RT Journal Article
SR Electronic
T1 Chronic Hemodialysis Patients have better outcomes with COVID-19 - a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159202
DO 10.1101/2020.07.22.20159202
A1 Naaraayan, Ashutossh
A1 Nimkar, Abhishek
A1 Hasan, Amrah
A1 Pant, Sushil
A1 Durdevic, Momcilo
A1 Elenius, Henrik
A1 Suarez, Corina Nava
A1 Basak, Prasanta
A1 Lakshmi, Kameswari
A1 Mandel, Michael
A1 Jesmajian, Stephen
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.22.20159202.abstract
AB Introduction Several comorbid conditions, have been identified as risk factors in patients with COVID-19. However, there is a dearth of data describing the impact of COVID-19 infection in patients with end-stage renal disease on hemodialysis (ESRD-HD).Methods This retrospective case series analyzed 362 adult patients consecutively hospitalized with confirmed COVID-19 illness between March 12, 2020 and May 13, 2020, at a teaching hospital in the New York City metropolitan area. Primary outcome was severe pneumonia as defined by the World Health Organization. Secondary outcomes were: 1) the Combined Outcome of Acute respiratory distress syndrome or in-hospital Death (COAD), and 2) the need for High-levels of Oxygen supplementation (HiO2).Results Patients with ESRD-HD had lower odds for poor outcomes including severe pneumonia [Odds Ratio (OR) 0.4, Confidence Interval (CI) (0.2–0.9) p=.04], HiO2 [OR 0.3, CI (0.1– 0.8) p=.02] and COAD [OR 0.4, CI (0.2–1.05) p=.06], when compared to patients without ESRD. In contrast, higher odds for severe pneumonia, COAD and HiO2 were seen with advancing age. African-Americans were over-represented in the hospitalized patient cohort, when compared to their representation in the community (35% vs 18%). Hispanics had higher odds for severe-illness and HiO2 when compared to Caucasians.Conclusions Patients with ESRD-HD had a milder course of illness with a lower likelihood of severe pneumonia and a lesser need for aggressive oxygen supplementation when compared to patients not on chronic dialysis. This “protective effect” might have a pathophysiologic basis and needs to be further explored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the departmental research review committee with a waiver of informed consent due to its retrospective design.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.